by Truveta staff | Oct 2, 2023 | Data
In the realm of medtech innovation, the margin for error is slim. Upwards of 90% of funding for an early-stage company may be allocated to engineering and clinical costs, making it essential for leaders to de-risk their clinical programs. Having access to a...
